Pimecrolimus

Atopic dermatitis is a chronic inflammatory skin disease. Patients often suffer from repeated pruritus and recurrent skin lesions, which seriously affect their quality of life. Long-term use of traditional glucocorticoids is prone to cause adverse reactions such as skin atrophy, leaving a significant clinical gap in long-term maintenance treatment. Pimecrolimus is an immunomodulatory drug belonging to the calcineurin inhibitor class. By inhibiting T cell activation and the release of inflammatory cytokines, it selectively inhibits the skin inflammatory response without affecting the growth of keratinocytes, and has no risk of glucocorticoid-related skin atrophy. Clinically, it is mainly used for short-term treatment and long-term intermittent maintenance treatment of mild to moderate atopic dermatitis in children aged 2 years and above. It can also be used as an adjuvant treatment for other inflammatory skin diseases such as seborrheic dermatitis and oral lichen planus, and is one of the core drugs for the long-term management of atopic dermatitis in children.

In recent years, the global pimecrolimus market size has remained at around USD 320 million, and the growth rate of the Chinese market has maintained in the range of 6%-8% in recent years. The core driving factors are the continuous increase in the prevalence of atopic dermatitis and the expanding demand for safe anti-inflammatory drugs from the pediatric patient population. In terms of competitive landscape, the original research product still occupies the main market share. Many domestic enterprises have arranged for the research and development of generic drugs. As the core barriers are mainly concentrated in the optimization of API synthesis process and impurity control technology, the number of approved generic drugs in China is small at present, and there is still large substitution space in the market.

The original research enterprise of pimecrolimus is Novartis, and the original trade name is Elidel. Its US compound patent expired in 2023, and its Chinese compound patent expired in 2017. The main dosage form of the original research product is 1% cream, with specifications of 15g/piece and 30g/piece. This dosage form has been included in the Chinese Listed Medicines Catalogue and also included in the FDA Reference Listed Drug Catalogue. In terms of domestic API registration, there is no approved domestic API registration number at present, and the number of imported API registrations is small. The pimecrolimus cream generic drugs of many domestic enterprises have been approved for marketing. (Data as of June 2025, please refer to the official website of CDE for the latest information)

CATO can provide a full set of impurity reference standards for pimecrolimus API. Most products are available from stock. For in-stock products, orders placed before 16:00 can be shipped on the same day. All products meet the compliance requirements of multiple regulations such as Chinese Pharmacopoeia and FDA, and can fully meet the full-process impurity analysis needs of pharmaceutical enterprises from API research and development to marketing application.